Articles
🇺🇸 AmericasExpert insights, opinion pieces, and in-depth analysis on pharmaceutical trends and FDA regulations.
FDA Approves First Treatment for Chronic Hepatitis Delta Virus Infection
The FDA has approved the first treatment for Chronic Hepatitis Delta Virus (HDV) infection, marking a significant milestone in liver disease management. This article explores the implications for pharmaceutical companies and investors.
Five Key Regulatory Updates to Watch at ASCO
This article highlights five crucial regulatory updates at ASCO, particularly focusing on Daraxonrasib and its potential impact on the pharmaceutical landscape.
Ibrance Heirs and Gilead's Tubulis Data at ASCO26
This article delves into the latest developments from ASCO26, focusing on Ibrance heirs and Gilead's Tubulis data. Discover the implications for pharmaceutical stakeholders.
The Future of Men's Health: A Federal Office on the Horizon
As discussions around a federal office of men's health gain momentum, the pharmaceutical industry must prepare for potential shifts in focus and investment. This article delves into the implications for pharma teams.
Biogen and Denali Abandon Parkinson's Drug After Study Setback
Biogen and Denali have decided to discontinue their drug for non-genetic Parkinson's disease following disappointing mid-stage study results. This article explores the implications for the pharmaceutical landscape.
Why One Health AI Unicorn is Offering Free Services
A leading health AI unicorn has decided to offer its services for free, raising questions about its strategy and implications for the pharma sector. This article explores the motivations and potential impacts of this decision.
Genentech's Strategy to Influence Pharma Reforms
Genentech is actively soliciting research to mitigate the impact of proposed pharmaceutical reforms in Washington. This article explores the implications for the industry.
Harnessing AI for Efficient Doctor's Office Check-Ins
This article discusses the potential of AI to revolutionize check-in and intake processes in healthcare, focusing on its implications for pharmaceutical companies.
The Seed Oil Panic: Implications for Cardiac Health
This article discusses how the growing panic around seed oils is negatively affecting cardiac patients and the pharmaceutical industry's response.
Latest Insights on Parkinson’s Drug Setback and Merck’s Lung Cancer Therapy
This article reviews recent developments in Parkinson’s drug trials and Merck’s lung cancer therapy, highlighting their implications for the pharmaceutical industry.
EU and US Split on AstraZeneca's Breast Cancer Drug Approval
AstraZeneca's breast cancer drug faces differing opinions from EU and US regulators. This article explores the implications for pharma stakeholders.
Merck-Kelun ADC's Strategic Wins and Takeda's Antitrust Loss
This article delves into Merck-Kelun ADC's recent achievements in China and the implications of Takeda's significant antitrust loss, providing strategic insights for business development teams and investors.
CDC's Mpox Page: Caught in Political Crosshairs
The CDC's mpox page faces scrutiny amid political tensions, raising questions for pharmaceutical stakeholders.
#ASCO26: Kelun's Phase 3 Lung Cancer Success with Merck
Kelun's Phase 3 study on lung cancer in partnership with Merck showcased significant success at ASCO26. This article explores the implications for the pharma industry.
Merck-Kelun Lung Cancer Drug Cuts Tumor Progression Risk by 65%
Merck-Kelun's recent trial results indicate a significant breakthrough in lung cancer treatment, with a 65% reduction in tumor progression risk. This article explores the implications for the pharmaceutical industry.
Senators Grill NIH Director: Key Insights for Pharma
In a recent hearing, senators posed three pivotal questions to NIH Director Jay Bhattacharya, shedding light on funding and research priorities. This article explores the implications for the pharmaceutical sector.
#ASCO26 Insights: Head and Neck Cancer Developments
This article reviews significant head and neck cancer findings from ASCO26, focusing on insights from J&J, Corbus, Summit, Akero, and Bicara. Discover the implications for pharmaceutical stakeholders.
Roche vs AstraZeneca: Top Oncology MSL Team Survey Insights
A recent survey reveals Roche's oncology MSL team narrowly surpasses AstraZeneca's. This article explores the implications for the pharmaceutical industry.
#ASCO26: Insights on VEGF Bispecifics from BioNTech-BMS and Pfizer-3SBio
This article delves into the new data released at ASCO26 regarding VEGF bispecifics from BioNTech-BMS and Pfizer-3SBio, highlighting implications for the pharmaceutical industry.
STAT+: Experimental Parkinson's Drug Fails Key Trial - Insights
The recent failure of a closely watched experimental drug for Parkinson's disease raises significant questions for the pharmaceutical landscape. This article examines the implications for business development and investment strategies.